Mankind Pharma signs up with Glenmark Pharmaceuticals for co-marketing of Remogliflozin Etabonate in India
Udaipur : Mankind Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd. today inked a sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India. Under the agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply Remogliflozin to Mankind. In April 2019, Glenmark received approval from the Drugs … Read more